Literature DB >> 7541220

Expression of immunoreactive and bioactive activin A protein in adult murine lung after bleomycin treatment.

T Matsuse1, Y Fukuchi, Y Eto, H Matsui, T Hosoi, T Oka, E Ohga, T Nagase, H Orimo.   

Abstract

Activin A is a homodimeric protein structurally and functionally related to transforming growth factor beta (TGF-beta), and the expression of activin A is modulated by TGF-beta. Here, we demonstrate the expression of activin A in normal and bleomycin (BLM)-treated murine lungs. ICR mice were treated with BLM intraperitoneally for 10 days, whereas saline vehicle was injected into control mice. Intra-alveolar fibrotic changes were observed in the lung tissue obtained from the mice at day 14 after the final BLM administration. Immunohistochemical studies using a polyclonal antibody to activin A revealed the presence of activin A in the bronchiolar epithelium and smooth muscle cells of veins in both control and BLM-treated mice. In the BLM-treated mice at days 7 and 14, the marked infiltration of immunoreactive alveolar macrophages was observed in the area of fibrotic changes. Bioactivity of activin A measured by erythroid differentiation factor assay in the conditioned medium of alveolar macrophages obtained from BLM-treated mice at day 14 was significantly increased. These findings indicate that alveolar macrophages are a potent source of activin A after BLM treatment. The present study demonstrates for the first time the abundant expression of activin A in murine lung tissues after BLM administration, suggesting that activin A may play a role in the pathogenesis of BLM-induced pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541220     DOI: 10.1165/ajrcmb.13.1.7541220

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  5 in total

1.  Expression of immunoreactive activin A protein in remodeling lesions associated with interstitial pulmonary fibrosis.

Authors:  T Matsuse; A Ikegami; E Ohga; T Hosoi; T Oka; K Kida; M Fukayama; S Inoue; T Nagase; Y Ouchi; Y Fukuchi
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

2.  Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

Authors:  Vera Ivanova; Olga B Garbuzenko; Kenneth R Reuhl; David C Reimer; Vitaly P Pozharov; Tamara Minko
Journal:  Eur J Pharm Biopharm       Date:  2012-12-08       Impact factor: 5.571

3.  Deficient Follistatin-like 3 Secretion by Asthmatic Airway Epithelium Impairs Fibroblast Regulation and Fibroblast-to-Myofibroblast Transition.

Authors:  Richard G James; Stephen R Reeves; Kaitlyn A Barrow; Maria P White; Veronika A Glukhova; Candace Haghighi; Dana Seyoum; Jason S Debley
Journal:  Am J Respir Cell Mol Biol       Date:  2018-07       Impact factor: 7.748

4.  Follistatin, an activin antagonist, ameliorates renal interstitial fibrosis in a rat model of unilateral ureteral obstruction.

Authors:  Akito Maeshima; Keiichiro Mishima; Shin Yamashita; Masao Nakasatomi; Masaaki Miya; Noriyuki Sakurai; Toru Sakairi; Hidekazu Ikeuchi; Keiju Hiromura; Yoshihisa Hasegawa; Itaru Kojima; Yoshihisa Nojima
Journal:  Biomed Res Int       Date:  2014-05-05       Impact factor: 3.411

Review 5.  Activin, neutrophils, and inflammation: just coincidence?

Authors:  Paschalis Sideras; Eirini Apostolou; Athanasios Stavropoulos; Alexandros Sountoulidis; Arianna Gavriil; Anastasia Apostolidou; Evangelos Andreakos
Journal:  Semin Immunopathol       Date:  2013-02-06       Impact factor: 9.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.